AU2012245491C1 - Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies - Google Patents

Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies Download PDF

Info

Publication number
AU2012245491C1
AU2012245491C1 AU2012245491A AU2012245491A AU2012245491C1 AU 2012245491 C1 AU2012245491 C1 AU 2012245491C1 AU 2012245491 A AU2012245491 A AU 2012245491A AU 2012245491 A AU2012245491 A AU 2012245491A AU 2012245491 C1 AU2012245491 C1 AU 2012245491C1
Authority
AU
Australia
Prior art keywords
seq
sequence
domain
erbb3
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012245491A
Other languages
English (en)
Other versions
AU2012245491A1 (en
AU2012245491B2 (en
Inventor
Sharlene Adams
Jason BAUM
Jonathan Basil Fitzgerald
Bryan Johnson
Neeraj Kohli
Alexey Alexandrovich Lugovskoy
Lihui Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merrimack Pharmaceuticals Inc
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of AU2012245491A1 publication Critical patent/AU2012245491A1/en
Priority to AU2017216490A priority Critical patent/AU2017216490A1/en
Application granted granted Critical
Publication of AU2012245491B2 publication Critical patent/AU2012245491B2/en
Publication of AU2012245491C1 publication Critical patent/AU2012245491C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012245491A 2011-04-19 2012-04-19 Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies Ceased AU2012245491C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017216490A AU2017216490A1 (en) 2011-04-19 2017-08-16 Monospecific and bispecific anti-IGF-IR and anti-ErbB3 antibodies

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161477089P 2011-04-19 2011-04-19
US61/477,089 2011-04-19
US201161539297P 2011-09-26 2011-09-26
US61/539,297 2011-09-26
US201161558192P 2011-11-10 2011-11-10
US61/558,192 2011-11-10
US201261619244P 2012-04-02 2012-04-02
US61/619,244 2012-04-02
PCT/US2012/034244 WO2012145507A2 (en) 2011-04-19 2012-04-19 Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017216490A Division AU2017216490A1 (en) 2011-04-19 2017-08-16 Monospecific and bispecific anti-IGF-IR and anti-ErbB3 antibodies

Publications (3)

Publication Number Publication Date
AU2012245491A1 AU2012245491A1 (en) 2013-10-31
AU2012245491B2 AU2012245491B2 (en) 2017-08-17
AU2012245491C1 true AU2012245491C1 (en) 2017-12-21

Family

ID=47021510

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012245491A Ceased AU2012245491C1 (en) 2011-04-19 2012-04-19 Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies
AU2017216490A Abandoned AU2017216490A1 (en) 2011-04-19 2017-08-16 Monospecific and bispecific anti-IGF-IR and anti-ErbB3 antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017216490A Abandoned AU2017216490A1 (en) 2011-04-19 2017-08-16 Monospecific and bispecific anti-IGF-IR and anti-ErbB3 antibodies

Country Status (20)

Country Link
US (4) US8476409B2 (cg-RX-API-DMAC7.html)
EP (2) EP3214096A3 (cg-RX-API-DMAC7.html)
JP (2) JP5588086B2 (cg-RX-API-DMAC7.html)
KR (2) KR20140138353A (cg-RX-API-DMAC7.html)
CN (2) CN105884900A (cg-RX-API-DMAC7.html)
AU (2) AU2012245491C1 (cg-RX-API-DMAC7.html)
BR (1) BR112013027021A2 (cg-RX-API-DMAC7.html)
CA (1) CA2833643A1 (cg-RX-API-DMAC7.html)
DK (1) DK2699602T3 (cg-RX-API-DMAC7.html)
ES (1) ES2625818T3 (cg-RX-API-DMAC7.html)
HK (1) HK1223383A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20170713T1 (cg-RX-API-DMAC7.html)
HU (1) HUE034276T2 (cg-RX-API-DMAC7.html)
IL (1) IL228957A0 (cg-RX-API-DMAC7.html)
MX (2) MX346486B (cg-RX-API-DMAC7.html)
PL (1) PL2699602T3 (cg-RX-API-DMAC7.html)
PT (1) PT2699602T (cg-RX-API-DMAC7.html)
SI (1) SI2699602T1 (cg-RX-API-DMAC7.html)
TW (1) TWI631136B (cg-RX-API-DMAC7.html)
WO (1) WO2012145507A2 (cg-RX-API-DMAC7.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101598229B1 (ko) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도
WO2011047180A1 (en) * 2009-10-14 2011-04-21 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
SG183532A1 (en) 2010-03-11 2012-09-27 Merrimack Pharmaceuticals Inc Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
HRP20170713T1 (hr) * 2011-04-19 2017-07-14 Merrimack Pharmaceuticals, Inc. Bispecifično anti-igf-1r i anti-erbb3 antitijelo
US20150231219A1 (en) * 2012-04-02 2015-08-20 Merrimack Pharmaceuticals, Inc. Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
CN104341504B (zh) * 2013-08-06 2017-10-24 百奥泰生物科技(广州)有限公司 双特异性抗体
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
CA2975829A1 (en) * 2014-02-20 2015-09-03 Merrimack Pharmaceuticals, Inc. Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
RS61379B1 (sr) * 2014-04-25 2021-02-26 Pf Medicament Antitelo na igf-1r i njegova upotreba kao usmerenog nosioca za lečenje kancera
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
US20180169230A1 (en) * 2015-05-29 2018-06-21 Merrimack Pharmaceuticals, Inc. Combination cancer therapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
SG10201913073YA (en) 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
US20170049775A1 (en) 2015-08-21 2017-02-23 Merrimack Pharmaceuticals, Inc. Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
CN114099437A (zh) 2015-10-16 2022-03-01 易普森生物制药有限公司 稳定喜树碱药物组合物
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
US20170233491A1 (en) 2016-01-19 2017-08-17 Merrimack Pharmaceuticals, Inc. Dosage and administration of combination therapies comprising istiratumab, uses and methods of treatment
EA201891732A1 (ru) * 2016-02-02 2019-02-28 Кадмон Корпорейшн, Ллк Биспецифичные связывающие белки для pd-l1 и kdr
US10723857B1 (en) * 2016-04-15 2020-07-28 United States Of America As Represented By The Administrator Of National Aeronautics And Space Administration Polyimide aerogels with reduced shrinkage from isothermal aging
WO2018045256A1 (en) * 2016-09-02 2018-03-08 Merrimack Pharmaceuticals, Inc. Combination of an erbb3 inhibitor, topoisomerase i inhibitor, and an alkylating agent to treat cancer
JP6825284B2 (ja) * 2016-09-21 2021-02-03 カシオ計算機株式会社 イメージ作成装置、イメージ作成方法、及び、プログラム
RU2761953C2 (ru) 2016-11-02 2021-12-14 Ипсен Биофарм Лтд. Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин)
RS64315B1 (sr) * 2017-05-04 2023-08-31 Acceleron Pharma Inc Fuzioni proteini tgf-beta receptora tipa ii i njihove upotrebe
CN107602702A (zh) 2017-09-22 2018-01-19 生标（上海）医疗器械科技有限公司 一种同时靶向人p185和血管内皮生长因子的抗体及其应用
GB201804094D0 (en) * 2018-03-14 2018-04-25 Ultrahuman Thirteen Ltd ERBB3 Binding agents
US10640576B2 (en) 2018-04-10 2020-05-05 Y-Biologics Inc. Cell engaging binding molecules
JP7407822B2 (ja) 2018-08-30 2024-01-04 エイチシーダブリュー バイオロジックス インコーポレイテッド 単鎖キメラポリペプチドおよびその使用
CN112888445B (zh) 2018-08-30 2025-06-10 免疫生物公司 治疗老年化相关病症的方法
EP4659757A2 (en) 2018-08-30 2025-12-10 ImmunityBio, Inc. Multi-chain chimeric polypeptides and uses thereof
WO2020257639A1 (en) 2019-06-21 2020-12-24 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
WO2021163369A2 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
JP2023519107A (ja) 2020-02-11 2023-05-10 エイチシーダブリュー バイオロジックス インコーポレイテッド 制御性ｔ細胞を活性化する方法
CN115362169A (zh) 2020-02-11 2022-11-18 Hcw生物科技公司 色谱树脂以及其用途
CN113512116B (zh) * 2020-04-10 2022-09-20 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用
JP7734693B2 (ja) 2020-04-29 2025-09-05 イミュニティーバイオ インコーポレイテッド 抗ｃｄ２６タンパク質及びそれらの使用法
JP2023527869A (ja) 2020-06-01 2023-06-30 エイチシーダブリュー バイオロジックス インコーポレイテッド 加齢関連障害の治療法
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
CN118043351A (zh) * 2021-08-31 2024-05-14 上海医药集团股份有限公司 靶向Siglec15的抗原结合蛋白及其用途
JP2025508939A (ja) 2022-03-02 2025-04-10 イミュニティーバイオ インコーポレイテッド 膵臓癌の治療方法
CN120623322B (zh) * 2025-08-14 2025-12-05 成都蓉生药业有限责任公司 一种人IgG Fc变体、基因片段、表达载体、宿主细胞、IgG抗体及人IgG Fc变体制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008140493A2 (en) * 2006-11-21 2008-11-20 The Regents Of The University Of Californina Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
WO2011047180A1 (en) * 2009-10-14 2011-04-21 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
PT896586E (pt) 1996-03-27 2007-01-31 Genentech Inc Anticorpos de erbb3
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
EP3263702A1 (en) 2000-10-06 2018-01-03 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
JPWO2002030954A1 (ja) 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
ES2344592T3 (es) * 2001-01-05 2010-09-01 Pfizer Inc. Anticuerpos frente al receptor del factor de crecimiento similar a la insulina i.
EP1383800A4 (en) 2001-04-02 2004-09-22 Idec Pharma Corp RECOMBINANT ANTIBODIES CO-EXPRESSED WITH GNTIII
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US7638605B2 (en) * 2003-05-01 2009-12-29 ImClone, LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
BRPI0611445A2 (pt) 2005-05-09 2010-09-08 Glycart Biotechnology Ag molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica
CA2646508A1 (en) * 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
KR101598229B1 (ko) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도
CA2679548C (en) * 2007-03-02 2015-01-27 Amgen Inc. Methods and compositions for treating tumor diseases
KR20100052545A (ko) * 2007-08-28 2010-05-19 바이오겐 아이덱 엠에이 인코포레이티드 Ｉｇｆ―１ｒ의 다중 에피토프에 결합하는 조성물
EP2860260A1 (en) 2008-04-11 2015-04-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
AU2009281721A1 (en) 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
US8362215B2 (en) 2009-04-29 2013-01-29 Trellis Bioscience, Llc Antibodies immunoreactive with heregulin-coupled HER3
BRPI1007602A2 (pt) * 2009-05-27 2016-02-16 Hoffmann La Roche "anticorpo tri ou tetraespecífico, método para preparação de um anticorpo triespecífico ou tetraespecífico, célula hospedeira, composição, composição farmacêutica e método para o tratamento de um paciente com necessidade de terapia"
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2771744A1 (en) 2009-08-21 2011-02-24 Merrimack Pharmaceuticals, Inc. Antibodies against the ectodomain of erbb3 and uses thereof
NZ598929A (en) 2009-09-01 2014-05-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
NZ600262A (en) 2009-12-22 2013-06-28 Roche Glycart Ag Anti-her3 antibodies and uses thereof
US8481687B2 (en) 2010-04-09 2013-07-09 Aveo Pharmaceuticals, Inc. Anti-ErbB3 antibodies
PH12013500333A1 (en) * 2010-08-20 2013-04-22 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
HRP20170713T1 (hr) 2011-04-19 2017-07-14 Merrimack Pharmaceuticals, Inc. Bispecifično anti-igf-1r i anti-erbb3 antitijelo
US20150231219A1 (en) 2012-04-02 2015-08-20 Merrimack Pharmaceuticals, Inc. Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies
CA2975829A1 (en) * 2014-02-20 2015-09-03 Merrimack Pharmaceuticals, Inc. Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
US20170233491A1 (en) * 2016-01-19 2017-08-17 Merrimack Pharmaceuticals, Inc. Dosage and administration of combination therapies comprising istiratumab, uses and methods of treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008140493A2 (en) * 2006-11-21 2008-11-20 The Regents Of The University Of Californina Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
WO2011047180A1 (en) * 2009-10-14 2011-04-21 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof

Also Published As

Publication number Publication date
PT2699602T (pt) 2017-06-12
US20130236459A1 (en) 2013-09-12
IL228957A0 (en) 2013-12-31
HK1223383A1 (zh) 2017-07-28
KR20140138353A (ko) 2014-12-03
WO2012145507A3 (en) 2013-11-07
US20160122438A9 (en) 2016-05-05
US20170051063A1 (en) 2017-02-23
JP2014158485A (ja) 2014-09-04
US8476409B2 (en) 2013-07-02
JP5588086B2 (ja) 2014-09-10
AU2012245491A1 (en) 2013-10-31
MX336197B (es) 2016-01-11
PL2699602T3 (pl) 2017-11-30
DK2699602T3 (en) 2017-06-06
CN103703026B (zh) 2015-08-26
CN105884900A (zh) 2016-08-24
US9938346B2 (en) 2018-04-10
HUE034276T2 (en) 2018-02-28
KR101517320B1 (ko) 2015-05-28
JP2014513950A (ja) 2014-06-19
EP3214096A3 (en) 2017-10-18
US9556274B2 (en) 2017-01-31
HRP20170713T1 (hr) 2017-07-14
EP2699602A2 (en) 2014-02-26
US20120269812A1 (en) 2012-10-25
AU2012245491B2 (en) 2017-08-17
ES2625818T3 (es) 2017-07-20
AU2017216490A1 (en) 2017-08-31
TW201302790A (zh) 2013-01-16
JP6214453B2 (ja) 2017-10-18
EP3214096A2 (en) 2017-09-06
BR112013027021A2 (pt) 2016-11-29
KR20140033050A (ko) 2014-03-17
EP2699602B1 (en) 2017-03-01
US20160137738A1 (en) 2016-05-19
WO2012145507A2 (en) 2012-10-26
TWI631136B (zh) 2018-08-01
MX2013012201A (es) 2014-05-28
SI2699602T1 (sl) 2017-06-30
CA2833643A1 (en) 2012-10-26
US9527914B2 (en) 2016-12-27
MX346486B (es) 2017-03-22
CN103703026A (zh) 2014-04-02

Similar Documents

Publication Publication Date Title
AU2012245491C1 (en) Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies
WO2013174873A1 (en) Multispecific antibodies
US20250236682A1 (en) Antigen-binding protein comprising two fc domains and use thereof
KR20220156526A (ko) 조작된 항-her2 이중특이성 단백질
CN118355030A (zh) 抗EGFR抗体、抗cMET抗体、抗VEGF抗体、多特异性抗体及其用途
HK1192889B (en) Bispecific anti-igf-1r and anti-erbb3 antibodies
HK1192889A (en) Bispecific anti-igf-1r and anti-erbb3 antibodies
CA3239553A1 (en) Human mesothelin binders
KR20250110345A (ko) 항-cd137 항체 및 사용 방법
WO2023092048A1 (en) Anti-tnf-alpha antibodies and compositions

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 07 AUG 2017

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 07 AUG 2017 AND 23 AUGUST 2017

FGA Letters patent sealed or granted (standard patent)
TH Corrigenda

Free format text: IN VOL 31 , NO 37 , PAGE(S) 5429 UNDER THE HEADING AMENDMENTS - APPLICATION FOR AMENDMENTS UNDER THE NAME MERRIMACK PHARMACEUTICALS, INC., APPLICATION NO. 2012245491 CORRECT THE DATE OF THE STATEMENTS FILED TO READ 07 AUG 2017 AND 23 AUG 2017

MK14 Patent ceased section 143(a) (annual fees not paid) or expired